EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The promise of TIL therapy for glioblastoma

Emma L Pristo, Kelly M Hotchkiss, Anna M Corcoran, Pamela Noldner, Hideho Okada, John W Hickey, Jose Conejo-Garcia, Beth Shaz, Mustafa Khasraw

Trends in Cancer · 2026

DOI: 10.1016/j.trecan.2025.10.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026. Verfasst von Emma L Pristo und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC, USA. Hauptthemen laut MEDLINE: Glioblastoma, Lymphocytes, Tumor-Infiltrating, Brain Neoplasms, Immunotherapy, Adoptive. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, University of Pennsylvania, Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in refractory melanoma and durable responses in lung cancer. Glioblastoma presents distinct challenges for immunotherapy, including profound tumor heterogeneity, low T cell infiltration, and an immunosuppressive microenvironment, but these same features highlight the unique rationale for TILs. Unlike monoclonal engineered approaches, TILs retain natural polyclonality, enabling recognition of a diverse set of tumor-associated antigens and potential adaptation to the evolving antigenic landscape. Preliminary studies have already shown that tumor-reactive TILs can be successfully isolated and expanded from glioblastoma specimens, providing feasibility for clinical translation. This review discusses the current landscape of TIL therapy in glioblastoma, highlights recent advancements, and discusses future directions and clinical translation to position TIL therapy as a promising and adaptable cellular immunotherapy for one of the most treatment-resistant human cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaLymphocytes, Tumor-InfiltratingBrain NeoplasmsImmunotherapy, AdoptiveHumansTumor MicroenvironmentAntigens, NeoplasmAnimalsTreatment Outcome

Stichwörter der Autor:innen

T cell therapyglioblastomaimmunotherapytumor-infiltrating lymphocytes

Substanzen

Antigens, Neoplasm

Autor:innen und Institutionen

  • The Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC, USA.
  • The Marcus Center for Cellular Cures, Duke University, Durham, NC, USA.
  • Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Department of Integrative Immunobiology, Duke University, Durham, NC, USA.
  • The Marcus Center for Cellular Cures, Duke University, Durham, NC, USA; Department of Pathology, Duke University, Durham, NC, USA.

Förderung

  • NINDS NIH HHS
  • University of Pennsylvania
  • Daiichi-Sankyo
  • Compass Therapeutics

Zitieren

APA

Pristo, E. L., Hotchkiss, K. M., Corcoran, A. M., Noldner, P., Okada, H., Hickey, J. W., Conejo-Garcia, J., Shaz, B., & Khasraw, M. (2026). The promise of TIL therapy for glioblastoma. Trends in Cancer. https://doi.org/10.1016/j.trecan.2025.10.003

Vancouver

Pristo EL, Hotchkiss KM, Corcoran AM, Noldner P, Okada H, Hickey JW, et al. The promise of TIL therapy for glioblastoma. Trends in Cancer. 2026. doi:10.1016/j.trecan.2025.10.003

BibTeX
@article{Pristo2026,
  author = {Pristo, Emma L and Hotchkiss, Kelly M and Corcoran, Anna M and Noldner, Pamela and Okada, Hideho and Hickey, John W and Conejo-Garcia, Jose and Shaz, Beth and Khasraw, Mustafa},
  title = {The promise of TIL therapy for glioblastoma},
  journal = {Trends in Cancer},
  year = {2026},
  doi = {10.1016/j.trecan.2025.10.003}
}
Kostenlos starten →